BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lai SW. Risk factors for hepatocellular carcinoma. Cancer 2019;125:482. [PMID: 30500069 DOI: 10.1002/cncr.31802] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
Number Citing Articles
1 Zhu J, Kong L, Chen Q, Li B, Wu L, Ran F, Ke L, Zeng X, Wang H. Design, Synthesis, and Apoptosis-Promoting Effect Evaluation of Rhopaladins’ Analog 4-Arylidene-5-Oxopyrrolidine Derivatives. Front Chem 2022;10:898436. [DOI: 10.3389/fchem.2022.898436] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Weinmann A, Galle PR. Role of immunotherapy in the management of hepatocellular carcinoma: current standards and future directions. Curr Oncol 2020;27:S152-64. [PMID: 33343209 DOI: 10.3747/co.27.7315] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Ghavimi S, Apfel T, Azimi H, Persaud A, Pyrsopoulos NT. Management and Treatment of Hepatocellular Carcinoma with Immunotherapy: A Review of Current and Future Options. J Clin Transl Hepatol. 2020;8:168-176. [PMID: 32832397 DOI: 10.14218/jcth.2020.00001] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 14.5] [Reference Citation Analysis]